Novo Nordisk Canada/Paladin Labs has recently announced the end of production of its GlucaGen HypoKit, following in the steps of Eli Lilly, who also recently stopped producing and selling its injectable glucagon emergency kit. The company specified that these products will no longer be available starting February 2024. The company’s decision is based on the … Read more
Hypoglycemia, or blood sugar that is lower than 4.0 mmol/L, is the most common complication in the treatment of type 1 diabetes (T1D). This condition affects the quality of life of people with T1D who experience it repeatedly. Hypoglycemia can manifest through unpleasant symptoms such as fatigue, sweating, tremors and palpitations. It must be treated … Read more
The Eli Lilly Company recently announced that it will stop producing and selling its emergency glucagon injection kit used to treat severe hypoglycemic episodes. In Canada, the product will no longer be available as of June 2023. The decision was made due to the decreased demand for injectable glucagon ever since nasal glucagon was made … Read more
Despite your and your child’s healthcare team’s best efforts to keep your child’s blood sugar within target, severe hypoglycemic episodes can happen, and it’s best to always be prepared for the unpredictable. Should your child not be able to safely ingest any glucose tablets or fruit juice, you’ll have to administer glucagon, a hormone that … Read more
Written August 2020, updated February 2023 People with type 1 diabetes (T1D) either use an insulin pump or multiple daily injections to take their insulin. Injection treatment requires using two types of insulin, and generally a total of four daily injections: One type of rapid-acting insulin, which is active for about four hours to cover … Read more
Maintaining blood sugar levels in range after meals is probably one of the toughest challenges that people with type 1 diabetes (T1D) have to face. Other than taking into account the countless, non-meal related factors that can impact blood sugar levels, they have to count the exact number of carbs they’re eating and anticipate how … Read more
Reference insulin products are increasingly being replaced with biosimilar types of insulin. Until recently, three biosimilar insulin products were available in Canada: Admelog, biosimilar version of Humalog Trurapi, biosimilar version of Novorapid Basaglar, biosimilar version of Lantus Biosimilar insulin products, just like generic products, are a “copy” of a reference drug. The main difference between … Read more
Anyone with type 1 diabetes (T1D) will tell you that a cure or a technological breakthrough has been highly anticipated for years! Although no miracles are expected in the short term, ongoing technological advances for diabetes management still help to alleviate the burden of living of T1D. And while there is still room for improvement … Read more
Living with type 1 diabetes (T1D) requires constant attention and relentless efforts to manage blood sugar levels, administer insulin multiple times a day, count carbs, worry about hypo- and hyperglycemia and avoid long-term complications, with no break, 24/7, 365 days a year. So, people with T1D get understandably excited when they hear about new burden-reducing … Read more
First published: July 2021 / Updated: November 2022 Approved in the United States as of November 17th, 2022, Tzield (Teplizumab) injection is the first drug to prevent and delay the onset of type 1 diabetes (T1D) in people at high risk of developing it in the short term. Teplizumab is currently in clinical trials in … Read more
